BRK is a member of the non-receptor tyrosine kinases (PTKs) that contains an amino terminal SH3 and SH2 domain as well as the catalytic domain (1). BRK expression is low or undetectable in normal mammary tissue and benign lesions. However, approximately two-thirds of breast tumors express appreciable levels, and 27% of tumors over express BRK by fivefold or more (2).
1. Mitchell, PJ. et al: Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene. 1994 Aug;9(8):2383-90.
2. Mitchell, PJ. et al: Characterisation and chromosome mapping of the human non receptor tyrosine kinase gene, brk. Oncogene. 1997 Sep 18;15(12):1497-502.Erratum in: Oncogene 1998 Jul 9;17(1):129.
Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.
Sample Purity Data. For specific information on a given lot, see related technical data sheet.
Storage, Stability and Shipping:
Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
RK Goel et al., The unique N-terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1. FEBS Journal September 2013 10.1111/febs.12420
Miah Sayem et al., BRK Targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration PLoS One February 2014 10.1371/journal.pone.0087684
Cancer, Cytoplasmic Tyrosine Kinases